LiGHT试验中重复选择性激光小梁成形术对未用药开角型青光眼及高眼压症的疗效
该研究为LiGHT试验的事后分析,纳入115眼(90例)未用药的开角型青光眼或高眼压症患者,因早期至中期失败需在18个月内重复360度SLT。结果显示重复SLT可维持无滴眼液的眼压控制至少18个月,且效果持续时间不短于初次激光。
要点
- 重复SLT后18个月,67%的115眼维持无滴眼液眼压控制。
- 初次SLT前眼压较重复SLT前高3.4 mmHg(95%CI 2.6-4.3,P<0.001)。
- 重复SLT未报告临床相关不良事件。
核心结论
- 重复SLT可在需要再次治疗的未用药开角型青光眼和高眼压症眼中维持眼压于目标值或以下,效果持续时间至少与初次激光相当。
研究设计与样本
- 多中心前瞻性随机对照试验(LiGHT试验)SLT治疗臂的事后分析。
- 纳入治疗初治的开角型青光眼或高眼压症眼,需在18个月内重复360度SLT。
- 重复治疗由预设的眼压和疾病进展标准(采用客观个体化目标眼压)触发。
- 共115眼(90例患者)接受重复SLT,第二次SLT后随访至少18个月。
主要发现
- 初次SLT前眼压显著高于重复SLT前眼压,平均差3.4 mmHg(95%CI 2.6-4.3,P<0.001)。
- 初次SLT后2个月绝对眼压降幅大于重复SLT,平均差1.0 mmHg(95%CI 0.2-1.8,P=0.02)。
- 调整激光前眼压后,重复SLT后2个月绝对眼压降幅更大,调整后平均差-1.1 mmHg(95%CI -1.7至-0.5,P=0.001)。
- 早期失败(初次SLT后2个月即重复治疗)34眼与后期失败(>2个月重复治疗)81眼,重复SLT后2个月绝对眼压降幅无显著差异,平均差0.3 mmHg(95%CI -1.1至1.8,P=0.655)。
- 重复SLT在18个月时使67%的115眼维持无滴眼液眼压控制,无临床相关不良事件。
关键数值与推荐
- 重复治疗触发标准为预设的眼压和疾病进展标准(采用客观个体化目标眼压)。
- 初次SLT前眼压较重复SLT前高3.4 mmHg(95%CI 2.6-4.3,P<0.001)。
- 初次SLT后2个月绝对眼压降幅较重复SLT大1.0 mmHg(95%CI 0.2-1.8,P=0.02)。
- 调整激光前眼压后,重复SLT后2个月绝对眼压降幅较初次SLT大1.1 mmHg(95%CI 0.5-1.7,P=0.001)。
- 重复SLT后18个月,67%的115眼维持无滴眼液眼压控制。
临床怎么用
- 对于未用药的开角型青光眼或高眼压症患者,若初次SLT后因早期至中期失败需再次治疗,重复SLT可考虑用于维持眼压控制。
- 重复SLT后眼压控制持续时间至少与初次激光相当,且未报告临床相关不良事件。
局限性
- 本研究为LiGHT试验SLT治疗臂的事后探索性分析。
- 重复治疗由预设的眼压和疾病进展标准触发,可能影响结果的外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the efficacy of repeat selective laser trabeculoplasty (SLT) in medication-naive open-angle glaucoma (OAG) and ocular hypertensive (OHT) patients requiring repeat treatment for early to medium-term failure during the Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. DESIGN: Post hoc analysis of SLT treatment arm of a multicenter prospective randomized controlled trial. PARTICIPANTS: Treatment-naive OAG or OHT requiring repeat 360-degree SLT within 18 months. Retreatment was triggered by predefined IOP and disease-progression criteria (using objective individualized target IOPs). METHODS: After SLT at baseline, patients were followed for a minimum of 18 months after second (repeat) SLT. A mixed-model analysis was performed with the eye as the unit of analysis, with crossed random effects to adjust for correlation between fellow eyes and repeated measures within eyes. Kaplan-Meier curves plot the duration of effect. MAIN OUTCOME MEASURES: Initial (early) IOP lowering at 2 months and duration of effect after initial and repeat SLT. RESULTS: A total of 115 eyes of 90 patients received repeat SLT during the first 18 months of the trial. Pretreatment IOP before initial SLT was significantly higher than before retreatment IOP of repeat SLT (mean difference, 3.4 mmHg; 95% confidence interval [CI], 2.6-4.3 mmHg; P < 0.001). Absolute IOP reduction at 2 months was greater after initial SLT compared with repeat SLT (mean difference, 1.0 mmHg; 95% CI, 0.2-1.8 mmHg; P = 0.02). Adjusted absolute IOP reduction at 2 months (adjusting for IOP before initial or repeat laser) was greater after repeat SLT (adjusted mean difference, -1.1 mmHg, 95% CI, -1.7 to -0.5 mmHg; P = 0.001). A total of 34 eyes were early failures (retreatment 2 months after initial SLT) versus 81 later failures (retreatment >2 months after initial SLT). No significant difference in early absolute IOP reduction at 2 months after repeat SLT was noted between early and later failures (mean difference, 0.3 mmHg; 95% CI, -1.1 to 1.8 mmHg; P = 0.655). Repeat SLT maintained drop-free IOP control in 67% of 115 eyes at 18 months, with no clinically relevant adverse events. CONCLUSIONS: These exploratory analyses demonstrate that repeat SLT can maintain IOP at or below target IOP in medication-naive OAG and OHT eyes requiring retreatment with at least an equivalent duration of effect to initial laser.
引用
- Garg A, Vickerstaff V, Nathwani N, et al. Efficacy of Repeat Selective Laser Trabeculoplasty in Medication-Naive Open-Angle Glaucoma and Ocular Hypertension during the LiGHT Trial. Ophthalmology. 2019. PMID: 32005561. doi:10.1016/j.ophtha.2019.10.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。